“The Report PharmaPoint: Major Depressive Disorder – Australia Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lillys Cymbalta, and Otsuka/BMSs Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takedas Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.
Despite patent expiries for key products, Eli Lillys Cymbalta in 2013, Otsuka Pharmaceutical/BMSs Abilify in 2016, and AstraZenecas Seroquel XR in 2017, the MDD market value in Australia is not anticipated to decline, as generic products are priced similarly to branded products and any loss of market value due to potential price discounts is expected to be offset by the increasing prevalent cases of MDD, the launch of Brintellix and the potential introduction of late-stage pipeline products during the forecast period.
Download Sample copy of this Report at : www.marketresearchreports.biz/sample/sample/208444
Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Australia including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Australia from 2013-2023.
Analysis of the impact of key events as well the drivers and restraints affecting the Australia Major depressive disorder market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2013-2023 in Australia.
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 12
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 15
3.2 Classification 17
3.3 Symptoms and Subtypes of Major Depressive Disorder 19
3.4 Prognosis 20
3.5 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 22
4.1.3 Clinical Practice 23
4.2 Australia 26
5 Competitive Assessment 29
5.1 Overview 29
5.2 Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors 31
5.2.1 Lexapro (Escitalopram) 31
5.2.2 Other Selective Serotonin Reuptake Inhibitors 35
5.3 Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors 38
5.3.1 Effexor (Venlafaxine) 38
5.3.2 Cymbalta (Duloxetine) 42
5.3.3 Pristiq (Desvenlafaxine) 46
5.4 Product Profiles: Major Brands, Other Antidepressants 50
5.4.1 Norepinephrine-Dopamine Reuptake Inhibitors 50
5.4.2 Noradrenaline and Specific Serotonergic Antidepressants 54
5.4.3 Monoamine Oxidase Inhibitors 58
5.4.4 Tricyclic Antidepressants 60
5.4.5 Brintellix (Vortioxetine) 62
5.5 Product Profiles: Major Brands, Antipsychotics 68
5.5.1 Abilify (Aripiprazole) 68
5.5.2 Seroquel XR (Quetiapine) 72
5.6 Other Therapeutic Classes 76
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207